CriticalAntidepressants. Other antidepressants of herbal origin×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
St John's wort induces the liver enzymes CYP3A4, CYP2B6, CYP2C9 and CYP2C19 and the transporter P-glycoprotein (St John's wort herbal monograph, European Medicines Agency, EMA). In the liver, CYP3A enzymes are the main route of ritonavir metabolism, so St John's wort lowers ritonavir blood levels and effect. Human immunodeficiency virus (HIV) treatment may then lose efficacy, and the virus may become resistant to ritonavir or to the whole class of protease inhibitors (ritonavir summary of product characteristics, SmPC, EMA, and ritonavir label, US Food and Drug Administration, FDA). When ritonavir is used as a booster, St John's wort also lowers the levels of the other drug: the lopinavir/ritonavir and nirmatrelvir/ritonavir documents describe a fall in both components (SmPCs of these products, EMA). The inducing effect may persist for at least 2 weeks after St John's wort is stopped (ritonavir and lopinavir/ritonavir SmPCs, EMA), although the herbal monograph says that the increased enzyme activity returns to normal within 1 week (St John's wort herbal monograph, EMA). The documents do not describe any effect of ritonavir on St John's wort.
Symptoms
The combination itself usually causes no symptoms: ritonavir and the drug it boosts lose their effect, the human immunodeficiency virus (HIV) viral load rises, and the virus may become resistant to treatment (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and ritonavir label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. During a short course of nirmatrelvir/ritonavir for COVID-19, St John's wort lowers the levels of both components and the effect of treatment (nirmatrelvir/ritonavir SmPC, EMA). After St John's wort is stopped, ritonavir levels may rise (ritonavir SmPC, EMA).
Management
The combination is contraindicated. St John's wort is on the ritonavir contraindication list as a product that lowers ritonavir levels and effect (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and ritonavir label, US Food and Drug Administration, FDA). The same contraindication appears in the documents of lopinavir/ritonavir and nirmatrelvir/ritonavir (SmPCs of these products, EMA, and nirmatrelvir/ritonavir FDA label). The St John's wort side has the same contraindication. The Spanish St John's wort product must not be taken with protease inhibitors, and its interaction table names ritonavir (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). However, the authorisation of this product has been suspended since June 2026, and there is no other current Spanish St John's wort SmPC. The EMA monograph contraindicates St John's wort with protease inhibitors for well-established use products, and for traditional use products when the daily hyperforin dose exceeds 1 mg (St John's wort herbal monograph, EMA). The ritonavir documents make no such dose exception. If a person is already taking St John's wort, stop it and measure the viral load if possible. The ritonavir dose may need adjusting, because ritonavir levels may rise after St John's wort is stopped (ritonavir SmPC, EMA). The inducing effect may persist for at least 2 weeks after St John's wort is stopped, and lopinavir/ritonavir can be started 2 weeks after the last St John's wort intake (ritonavir and lopinavir/ritonavir SmPCs, EMA). Do not start a course of nirmatrelvir/ritonavir immediately after stopping St John's wort. To choose when to start, consider a joint decision by doctors and clinical pharmacologists, bearing in mind that treatment starts within 5 days of symptom onset (nirmatrelvir/ritonavir SmPC, EMA, and FDA label). Before starting ritonavir and during treatment, consider possible interactions and review all concomitant medicines (ritonavir FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Nirmatrelvir/ritonavir (EU/1/22/1625), sección 4.3 (2026)– EMA, Paxlovid, ficha técnica en CIMA (nº registro 1221625001), consultada 03.10.2026, secciones 4.3 y 4.5
- FDA: PAXLOVID (nirmatrelvir; ritonavir) prescribing information (2026)– FDA, DailyMed setid 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a, revisión 02/2026 (versión 12), secciones 4 y 7.3
- EMA: Ficha técnica: Lopinavir/ritonavir, Kaletra (EU/1/01/172), sección 4.3 (2026)– EMA, Kaletra 100 mg/25 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 01172006, consultada 18.10.2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5